FDA has approved WELIREG for the treatment of adult patients with advanced RCC following a programmed death receptor-1 or programmed death-ligand 1 inhibitor and a VEGF-TKI.
Merck known as MSD outside of the United States and Canada, announced that FDA has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death…